Good news for healthcare premiums

Laura Pedulli | | Health Exec | Economics

A study from the Urban Institute finds that healthcare premiums throughout the U.S. will remain flat or drop during 2015, reports The Hill.

Only two out of 17 states surveyed will see premiums rise 5 percent or more, which marks the second consecutive year of modest increases, according to the article.

“I think it says a lot,” said John Holahan, a health policy fellow at the Urban Institute who co-authored the report. “I think it’s a good story, a good outcome, of at least one aspect of the Affordable Care Act. What it intended to do seems to be working.”

Read more below:

Report: Healthcare premium increases 'quite low' in 2015

Laura Pedulli

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.